Form 4: Bio-Rad Executive Reports RSU Vesting and Stock Transactions

Bio-Rad Laboratories EVP, President, CDG Eva Anette Engelhardt reported the vesting of restricted stock units and related stock transactions.

Summary

• Eva Anette Engelhardt, EVP, President, CDG of Bio-Rad Laboratories, reported transactions involving the company's Class A common stock and Restricted Stock Units (RSUs).
• On September 5, 2025, Engelhardt acquired 4,110 Restricted Stock Units.
• On September 6, 2025, 1,152 Restricted Stock Units vested, resulting in the acquisition of 1,152 shares of Bio-Rad Class A common stock.
• Concurrently, 413 shares of Bio-Rad Class A common stock were disposed of at a price of $295.43 per share, likely for tax withholding purposes related to the RSU vesting.
• Following these transactions, Engelhardt directly beneficially owns 896 shares of Bio-Rad Class A common stock and 3,456 Restricted Stock Units.
• The RSUs represent a contingent right to receive one share of Class A common stock each and vest over four years at 25% per year on the yearly anniversary date of the grant.

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation events, including the vesting of RSUs and the acquisition of new RSUs, which generally align executive interests with shareholders. The disposition of shares was for tax purposes, a standard practice.

Positives

• The acquisition of 4,110 new Restricted Stock Units indicates continued long-term incentive alignment for a key executive.
• The vesting of 1,152 RSUs and subsequent acquisition of common stock increases the executive's direct ownership in the company, demonstrating commitment.

Negatives

• The disposition of 413 shares for tax withholding reduces the immediate net share gain from the vesting event.

Related Party Transactions

• The reported transactions are related-party transactions as they involve an executive officer of Bio-Rad Laboratories, Inc. acquiring and disposing of company securities.

Stakeholder Impact

• Shareholders: The transactions reflect standard executive compensation practices, aligning the executive's interests with long-term company performance through equity ownership. The disposition for tax purposes is a routine event and does not indicate a lack of confidence.

Next Steps

• Future vesting events for the remaining 3,456 Restricted Stock Units will occur annually at 25% per year on the anniversary date of the grant.

Key Dates

Recommendation

The filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and subsequent tax-related share disposition. These events are generally pre-scheduled and do not indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, the filing itself does not provide new information warranting a change from a 'hold' position, assuming the investor's existing thesis remains intact.

Keywords

Bio-Rad Laboratories, BIO, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Eva Anette Engelhardt, Stock Transactions, Corporate Governance